Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension (PAH) to the U.S. FDA

Contributed by: PR Newswire

Tags

CERENO-SCIENTIFIC-CS1

More Like This

Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications

Pulnovo Medical Announces First Enrollment in Portugal for Global Clinical Study of PADN Technology in Treating Pulmonary Hypertension Associated with Left Heart Disease

PR Newswire associated0

Daewoong Pharmaceutical Presents Phase 2 Clinical Trial Poster on 'Bersiporocin' at ATS 2025, Highlights Global Patient Demographics

Pulnovo Medical Announces Joining PHA's (Pulmonary Hypertension Association) Corporate Committee

VASTHERA Receives U.S. FDA Clearance to initiate Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10

Sepul Bio, an innovative business unit of Théa, Doses First Participant in Phase 3 HYPERION clinical trial of sepofarsen for CEP290-associated Leber Congenital Amaurosis Type 10

Pulnovo Medical Announces Closing of Nearly $100 Million Series C Financing

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial